Exhibit 99.1
Eterna TherapeuticsInvestor Presentation August 2023 1 © Eterna Therapeutics
Inc.
This presentation (this “Presentation”) and any oral statements made in connection
with this Presentation are for informational purposes only and do not constitute an offer to sell, a solicitation of an offer to buy, or a recommendation to purchase any equity, debt or other securities of Eterna Therapeutics Inc., a Delaware
corporation (including its consolidated subsidiaries and affiliates, the “Company”). The information contained herein does not purport to be all inclusive. The data contained herein is derived from various internal and external sources believed
to be reliable, but there can be no assurance as to the accuracy or completeness of such information. Any data on past performance contained herein is not an indication as to future performance. Except as required by applicable law, the Company
assumes no obligation to update the information in this Presentation. Nothing herein shall be deemed to constitute investment, legal, tax, financial, accounting or other advice. The communication of this Presentation is restricted by law, and
it is not intended for distribution to, or use by any person in, any jurisdiction where such distribution or use would be contrary to local law or regulation. Forward-Looking Statements This Presentation includes certain “forward-looking
statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may address, among other things, the Company’s expected plans and prospects, including without limitation, the Company’s
views with respect to the potential for mRNA Cell Engineering, its expectations with respect to timing of regulatory filings and the reporting of initial data from any clinical trial(s), the potential therapeutic opportunities for mRNA Cell
Engineering, its expectations regarding its product strategies, and its plans regarding commercialization of mRNA Cell Engineering. These forward-looking statements are distinguished by use of words such as “anticipate,” “aim,” “believe,”
“continue,” “can,” “could,” “designed to,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would” and the negative of these terms, and similar references to future
periods. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from these expectations due to, among other things, the Company’s ability
to discover and develop novel drug candidates and delivery approaches, the Company’s ability to successfully demonstrate the efficacy and safety of its drug candidates, the pre-clinical and clinical results for its product candidates, which may
not support further development of product candidates, the actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials, obtaining, maintaining and protecting intellectual property, the Company’s
ability to enforce its patents against infringers and defend its patent portfolio against challenges from third parties, obtaining regulatory approval for products, competition from others using technology similar to the Company’s and others
developing products for similar uses, the Company’s ability to manage operating expenses, the Company’s ability to obtain additional funding to support its business activities and establish and maintain strategic business alliances and new
business initiatives, the Company’s dependence on third parties for development, manufacture, marketing, sales and distribution of products, the outcome of litigation, and unexpected expenditures. Detailed information about these factors and
additional important factors can be found in the documents that the Company files with the Securities and Exchange Commission, such as Form 10-K, Form 10-Q and Form 8-K. Forward-looking statements speak only as of the date the statements were
made. The Company does not undertake an obligation to update forward-looking information, except to the extent required by applicable law. Legal Notices 2 © Eterna Therapeutics Inc.
Investment Highlights 3 © Eterna Therapeutics Inc. Novel technologies primed to
generate value through collaborations and partnerships, and compete in growing, multi-billion dollar markets Gene editing and mRNA delivery technology instrumental for R&D in cell engineering Technology is protected by a diligently
prosecuted patent portfolio with over 130 granted patents Corporate strategy designed to maximize value of technologies and runway, while ensuring continued progress for key activities
Primed to Compete in Growing, Multi-billion $ Markets Eterna’s technology is
designed to potentially help solve a variety of industry problems, including efficient editing and delivery *Verified Market Research;**Nova1Advisor CAGR 4.7% CAGR 16.52%
5 © Eterna Therapeutics Inc. Each platform is supported by a significant
intellectual property estate with patents designed to both support and foster candidate development and trademarks designed to provide additional brand exclusivity and recognition The Eterna Platform RNA ToRNAdo™ RNA Delivery Gene Editing
Platforms Technology RNAGene Editing RNA Cell Reprogramming Applications Library of Ionizable Lipids Eterna: An Innovative RNA Cell Engineering Company
Substantial Shortcomings Remain with Industry Standard Gene Editing
Technologies 6 © Eterna Therapeutics Inc. Other Technologies in Use Key Shortcomings TALENs CRISPR Can be complex or can require expensive customization Immunogenic Potential cause of autoimmune diseases Potential for undesired
mutations (“off-target effects”) Potential for undesired genome disruption Delivery challenges
7 © Eterna Therapeutics Inc. Eterna’s platform is novel and differentiated with
the potential to overcome the challenges of industry standard cell engineering technologies The Eterna Platform RNA ToRNAdo™ RNA Delivery Gene Editing Platforms Technology Library of Ionizable Lipids Potential Advantages Immunogenicity
not expected Issues with off-target effects not expected Issues with genomic disruption not expected Efficient delivery Potential Advantages of Eterna’s Novel RNA Technologies with Gene Editing and Cell Reprogramming Applications
8 © Eterna Therapeutics Inc Potential for
high-value therapeutics CORE POTENTIAL MODALITIES POTENTIAL THERAPEUTICS Gene editing Blood cancers Gene replacement Solid tumors Cell replacement Ophthalmology, cardiology, neurology, etc. Reprogramming, Gene Editing,
Delivery Cell Therapy Oncology Pipeline ISO Class 7 Cleanroom Facility RNA Research Lab, Equipment, and Staff Foundational Patent Portfolio Partnership Strategy Offers Multiple Potential Paths to Revenue Upfront license
payments, milestones & royalties Partner-funded product co-development Partner-funded joint ventures
RiboSlice™: Non-Viral, DNA-Free Targeted Gene Editing 9 © Eterna Therapeutics
Inc. RiboSlice™: mRNA construct that encodes gene editing proteins mRNA transiently expresses high levels of gene editing proteins within cells Does not rely on viruses or DNA-based vectors Potential to enable efficient and effective single
or multiplexed editing Potential RiboSlice™ Application: Allogeneic CAR-T Example application: Allogeneic CAR-T RiboSlice™ used to knock out endogenous TCR to prevent therapeutic T cells from causing graft-versus-host disease
(GvHD) RiboSlice™ mRNA can be delivered via ToRNAdo™ or electroporation CAR can be inserted using RiboSlice™ or traditional lentiviral approaches High-efficiency gene editing of TRAC and PD1 in human cells Eterna Gene-Editing Technologies
NoveSlice™: high specificity gene-editing endonuclease Exhibits high efficiency
on-target cutting and enhanced sensitivity to the chromatin context of the target site Designed with an array of DNA-binding repeat sequences connected by flexible linkers Designed to target cutting activity to actively expressed genes, with
the potential to: reduce off-target effects minimize cellular toxicity enable enhanced safety for future potential therapeutics High-efficiency gene editing of the AAVS1 genomic safe harbor locus in human iPSCs © Eterna Therapeutics
Inc. 10 NoveSlice™: Chromatin Context Sensitive Gene-Editing Endonuclease Eterna Gene-Editing Technologies
The Eterna Difference: Eterna’s LNP Delivery is Customizable Through Its Library
of Novel Ionizable Lipids 11 © Eterna Therapeutics Inc. Designed to effectively transfect cells Customizable constructs allow Eterna to vary the lipid head group, tail, and spacer link to fine tune the lipid transfection ability Exploring
tropism for traditionally difficult to target tissues: heart, solid tumors, spleen, kidney Lipid Technology
Ionizable Lipids Have Demonstrated Robust Transfection 12 © Eterna Therapeutics
Inc. Transfection efficiency may be increased by fine tuning with only a few highly targeted edits to the structure Eterna LNPs and lipoplexes exhibited greater in vitro transfection efficiency of THP-1 monocytes than commercially-available
controls Transfection of Jurkat T cells Lipoplex Screen in THP-1 Monocytes Jurkat T Cell Transfection Lipid Technology
Eterna’s mRNA Delivery Capabilities to Target the Lungs 13 © Eterna
Therapeutics Inc. Transgene expression observed as early as 4 h after transfection in BEAS2B cells treated with both nebulized and non-nebulized complexes and was maintained to at least 48 h(Figs. A–E) Fluorescent images of nebulized
formulated mRNA 48 h after administration to the rat lung showed a clear pattern of GFP fluorescence in epithelial cells (Fig. D) and quantitative assessment showed GFP at a concentration of 35,000 pg/g of homogenized lung tissue Robust
expression even at 48 h (Fig. E) Eterna’s semisynthetic mRNA technology to reduce ARDS severity Aerosolized Pulmonary Delivery of mRNA Constructs Attenuates Severity of Escherichia coli Pneumonia in the Rat, Sean D. McCarthy, Christopher B.
Rohde, Matt Angel, Claire H. Masterson, Ronan MacLoughlin, Juan Fandiño, Héctor E. González, Declan Byrnes, John G. Laffey, and Daniel O'Toole. Nucleic Acid Therapeutics 2023 33:2, 148-158 Lipid Technology
Eterna’s mRNA Delivery Capabilities to Target the Lungs 14 © Eterna
Therapeutics Inc. IkBα and SOD3 expression significantly increased in vitro and in vivo in pulmonary cells administered respective complexes compared to those receiving scrambled mRNA control A B C D Aerosolized Pulmonary Delivery of
mRNA Constructs Attenuates Severity of Escherichia coli Pneumonia in the Rat, Sean D. McCarthy, Christopher B. Rohde, Matt Angel, Claire H. Masterson, Ronan MacLoughlin, Juan Fandiño, Héctor E. González, Declan Byrnes, John G. Laffey, and
Daniel O'Toole. Nucleic Acid Therapeutics 2023 33:2, 148-158 Lipid Technology
Platform to Address Challenges of Cell Reprogramming 15 © Eterna Therapeutics
Inc. Allogeneic “off-the-shelf” cell therapies can be a very powerful tool in treating a variety of diseases Eterna’s technology aims to address the challenges facing allogeneic “off-the-shelf” cell therapies including increasing the
expansion potential and reducing the in vivo persistence by minimizing host immune rejection Cell Reprogramming Challenges and Eterna Approach Cell Reprogramming
16 © Eterna Therapeutics Inc. iPSC Markers for Confirmation Clonal iPSC Lines
Generated in 2 Weeks mRNA Transfections with Eterna Technology Verified iPSC Differentiation Potential Mesenchymal Stem Cells Adipocytes Oil Red O stain Chondrocytes Alcian Blue stain Osteoblasts Alizarin Red S stain Functional
Cardiomyocytes Neurons β-tubulin Retinal Pigment Epithelial Cells Natural Killer Cells Macrophages Eterna Technology Efficiently Reprograms Cells with mRNA to iPSCs that can Differentiate into Multiple Tissues and Cell Types Cell
Reprogramming
Combined mRNA Gene Editing and Cell Reprogramming Creation of pluripotent stem
cell lines containing defined deletions in the CCR5 gene Demonstrated gene editing and dedifferentiation of human somatic cells in preclinical studies Successful demonstration of capability to generate clonal engineered pluripotent stem cell
lines 17 © Eterna Therapeutics Inc. Cell Reprogramming
Summary Highlights 18 © Eterna Therapeutics Inc. Novel technologies primed to
generate value through collaborations and partnerships, and compete in growing, multi-billion dollar markets Partnership strategy is well positioned to maximize several potential revenue streams including upfront payments, milestones,
royalties, and partner funded co-development and joint ventures Gene editing and mRNA delivery technology instrumental for R&D in cell engineering Technology is protected by a diligently prosecuted patent portfolio with over 130 granted
patents Corporate strategy designed to maximize value of technologies and runway, while ensuring continued progress for key activities